|
Age, median (mean +/− SD), y
|
46 +/− 9
|
53 +/− 12
|
0.12
|
|
Gender, n (%)
| | |
0.16
|
|
Male
|
5 (62)
|
1 (8)
| |
|
Female
|
8 (38)
|
11 (92)
| |
|
Body mass index, (mean +/− SD)
|
28 (5)
|
24 (3)
|
0.09
|
|
Lesion site, n (%)
| | |
> 0.99
|
|
Right
|
9 (69)
|
8 (67)
| |
|
Left
|
4 (31)
|
4 (33)
| |
|
Unilateral
|
9 (69)
|
12 (100)
| |
|
Bilateral
|
4 (31)
|
0
| |
|
Severity, n (%)
| | |
> 0.99
|
|
Mild
|
5 (62)
|
4 (33)
| |
|
Moderate
|
8 (38)
|
8 (67)
| |
|
Baseline visual analogue scale, (mean +/− SD)
|
2.4 +/− 2.5
|
2.6 +/− 2.0
|
0.60
|
|
Baseline symptom severity score, (mean +/− SD)
|
21 +/− 6.4
|
22 +/− 5.1
|
0.63
|
|
Baseline functional score, (mean +/− SD)
|
14 +/− 3.2
|
12 +/− 4.1
|
0.16
|
|
Baseline Boston questionnaire score, (mean +/− SD)
|
35 +/− 8.5
|
34 +/− 8.5
|
0.77
|
|
Baseline peak sensory distal latency, (mean +/− SD)
|
4.5 +/− 0.72
|
3.7 +/− 1.3
|
0.057
|
|
Baseline SNAPc amplitude, (mean +/− SD)
|
17 +/− 6.9
|
18 +/− 10
|
0.72
|
|
Baseline motor distal latency, (mean +/− SD)
|
4.5 +/− 0.35
|
4.7 +/− 0.90
|
0.57
|
|
Baseline CMAPd amplitude, (mean +/− SD)
|
6.9 +/− 1.5
|
6.0 +/− 0.61
|
0.16
|
